Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 470

1.

Prostanoid EP4 receptor-mediated augmentation of Ih currents in Aβ dorsal root ganglion neurons underlies neuropathic pain.

Zhang H, Kashihara T, Nakada T, Tanaka S, Ishida K, Fuseya S, Kawagishi H, Kiyosawa K, Kawamata M, Yamada M.

J Pharmacol Exp Ther. 2018 Nov 8. pii: jpet.118.252767. doi: 10.1124/jpet.118.252767. [Epub ahead of print]

2.

Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals.

Sugiura A, Joshita S, Umemura T, Yamazaki T, Fujimori N, Kimura T, Matsumoto A, Igarashi K, Usami Y, Wada S, Mori H, Shibata S, Yoshizawa K, Morita S, Furuta K, Kamijo A, Iijima A, Kako S, Maruyama A, Kobayashi M, Komatsu M, Matsumura M, Miyabayashi C, Ichijo T, Takeuchi A, Koike Y, Gibo Y, Tsukadaira T, Inada H, Kiyosawa K, Tanaka E.

J Viral Hepat. 2018 Jul 25. doi: 10.1111/jvh.12973. [Epub ahead of print]

PMID:
30044517
3.

Reappraisal of attenuated insulin sensitivity in the evolution of non-alcoholic fatty liver disease.

Miyakoshi T, Sagesaka H, Sato Y, Hirbayashi K, Koike H, Yamashita K, Usuda S, Kiyosawa K, Shimodaira M, Aizawa T.

Eur J Clin Nutr. 2018 Jul 17. doi: 10.1038/s41430-018-0246-3. [Epub ahead of print]

PMID:
30018458
4.

Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers.

Kawaguchi T, Shima T, Mizuno M, Mitsumoto Y, Umemura A, Kanbara Y, Tanaka S, Sumida Y, Yasui K, Takahashi M, Matsuo K, Itoh Y, Tokushige K, Hashimoto E, Kiyosawa K, Kawaguchi M, Itoh H, Uto H, Komorizono Y, Shirabe K, Takami S, Takamura T, Kawanaka M, Yamada R, Matsuda F, Okanoue T.

PLoS One. 2018 Jan 31;13(1):e0185490. doi: 10.1371/journal.pone.0185490. eCollection 2018.

5.

Successful Treatment for Chronic Hepatitis C-Autoimmune Hepatitis Overlap Syndrome due to Daclatasvir and Asunaprevir.

Sugiura A, Wada S, Mori H, Kimura T, Matsuda Y, Tanaka N, Tanaka E, Kiyosawa K.

Case Rep Gastroenterol. 2017 May 17;11(2):305-311. doi: 10.1159/000475752. eCollection 2017 May-Aug.

6.

Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial.

Maruyama M, Tanaka N, Kubota D, Miyajima M, Kimura T, Tokutake K, Imai R, Fujisawa T, Mori H, Matsuda Y, Wada S, Horiuchi A, Kiyosawa K.

Can J Gastroenterol Hepatol. 2017;2017:4385161. doi: 10.1155/2017/4385161. Epub 2017 Feb 28.

7.

[Retrospective Review of Labor Analgesia for Parturients with Moyamoya Disease.]

Hosokawa Y, Kiyosawa K, Kato R, Okutomi T, Okamoto H.

Masui. 2016 Sep;65(8):811-816. Japanese.

PMID:
30351592
8.

Clinicopathological characteristics of non-B non-C hepatocellular carcinoma without past hepatitis B virus infection.

Kimura T, Kobayashi A, Tanaka N, Sano K, Komatsu M, Fujimori N, Yamazaki T, Shibata S, Ichikawa Y, Joshita S, Umemura T, Matsumoto A, Horiuchi A, Mori H, Wada S, Kiyosawa K, Miyagawa SI, Tanaka E.

Hepatol Res. 2017 Apr;47(5):405-418. doi: 10.1111/hepr.12762. Epub 2016 Jul 24.

PMID:
27288988
9.

[Anesthetic Management of a Patient with Facioscapulohumeral Muscular Dystrophy: Importance of Monitoring Neuromuscular Function at Multiple Sites].

Matsui S, Tanaka S, Kiyosawa K, Tanaka T, Kawamata M.

Masui. 2015 Dec;64(12):1273-6. Japanese.

PMID:
26790332
10.

Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study.

Tateishi R, Okanoue T, Fujiwara N, Okita K, Kiyosawa K, Omata M, Kumada H, Hayashi N, Koike K.

J Gastroenterol. 2015 Mar;50(3):350-60. doi: 10.1007/s00535-014-0973-8. Epub 2014 Jun 15.

11.

KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.

Umemura T, Ota M, Katsuyama Y, Wada S, Mori H, Maruyama A, Shibata S, Nozawa Y, Kimura T, Morita S, Joshita S, Komatsu M, Matsumoto A, Kamijo A, Kobayashi M, Takamatsu M, Yoshizawa K, Kiyosawa K, Tanaka E.

Hum Immunol. 2014 Aug;75(8):822-6. doi: 10.1016/j.humimm.2014.06.003. Epub 2014 Jun 11.

PMID:
24929144
12.

[Chemotherapy using gemcitabine hydrochloride for malignant lymphoma].

Asou H, Maeda K, Takeuchi K, Kiyosawa K, Taniai H.

Gan To Kagaku Ryoho. 2013 Nov;40(11):1489-95. Review. Japanese.

PMID:
24231701
13.

[Combined spinal-epidural anesthesia for caesarean section in a parturient with scoliosis].

Kiyosawa K, Kawamata T, Yamamoto K, Kawamata M.

Masui. 2013 Jul;62(7):859-62. Japanese.

PMID:
23905412
14.
15.

Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.

Okamoto I, Aoe K, Kato T, Hosomi Y, Yokoyama A, Imamura F, Kiura K, Hirashima T, Nishio M, Nogami N, Okamoto H, Saka H, Yamamoto N, Yoshizuka N, Sekiguchi R, Kiyosawa K, Nakagawa K, Tamura T.

Invest New Drugs. 2013 Oct;31(5):1275-82. doi: 10.1007/s10637-013-9941-z. Epub 2013 Mar 10. Erratum in: Invest New Drugs. 2013 Oct;31(5):1395-6.

PMID:
23475281
16.

Steroid-free living donor liver transplantation for HCV--a multicenter prospective cohort study in Japan.

Marubashi S, Umeshita K, Asahara T, Fujiwara K, Haga H, Hashimoto T, Hatakeyama K, Ichida T, Kanematsu T, Kitajima M, Kiyosawa K, Makuuchi M, Miyagawa S, Satomi S, Soejima Y, Takada Y, Tanaka N, Teraoka S, Monden M.

Clin Transplant. 2012 Nov-Dec;26(6):857-67. doi: 10.1111/j.1399-0012.2012.01627.x. Epub 2012 Apr 16.

PMID:
22507465
17.

Long-term outcome of Japanese patients with type 1 autoimmune hepatitis.

Yoshizawa K, Matsumoto A, Ichijo T, Umemura T, Joshita S, Komatsu M, Tanaka N, Tanaka E, Ota M, Katsuyama Y, Kiyosawa K, Abe M, Onji M.

Hepatology. 2012 Aug;56(2):668-76. doi: 10.1002/hep.25658. Epub 2012 Jul 6.

PMID:
22334246
18.

[HGV related viral marker].

Kobayashi M, Kiyosawa K.

Nihon Rinsho. 2010 Jun;68 Suppl 6:462-4. Japanese. No abstract available.

PMID:
20942104
19.

Clinical significance of immunoglobulin G4-associated autoimmune hepatitis.

Umemura T, Zen Y, Hamano H, Joshita S, Ichijo T, Yoshizawa K, Kiyosawa K, Ota M, Kawa S, Nakanuma Y, Tanaka E.

J Gastroenterol. 2011 Jan;46 Suppl 1:48-55. doi: 10.1007/s00535-010-0323-4. Epub 2010 Sep 23.

PMID:
20862498
20.

Another cause of autoimmune hepatitis.

Umemura T, Zen Y, Nakanuma Y, Kiyosawa K.

Hepatology. 2010 Jul;52(1):389-90. doi: 10.1002/hep.23730. No abstract available.

PMID:
20578154
21.

Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection.

Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, Hayashi N, Sato C, Kiyosawa K, Tanikawa K, Ishikawa H, Masaki N, Seriu T, Omata M.

J Hepatol. 2010 Jun;52(6):791-9. doi: 10.1016/j.jhep.2009.12.036. Epub 2010 Mar 24.

PMID:
20409606
22.

Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B.

Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwasaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Tenney DJ, Omata M.

Hepatol Int. 2009 Jun;3(2):403-10. doi: 10.1007/s12072-008-9108-8. Epub 2008 Dec 9.

23.

Donor complications associated with living donor liver transplantation in Japan.

Hashikura Y, Ichida T, Umeshita K, Kawasaki S, Mizokami M, Mochida S, Yanaga K, Monden M, Kiyosawa K; Japanese Liver Transplantation Society.

Transplantation. 2009 Jul 15;88(1):110-4. doi: 10.1097/TP.0b013e3181aaccb0.

PMID:
19584689
24.

Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress.

Okiyama W, Tanaka N, Nakajima T, Tanaka E, Kiyosawa K, Gonzalez FJ, Aoyama T.

J Hepatol. 2009 Jun;50(6):1236-46. doi: 10.1016/j.jhep.2009.01.025. Epub 2009 Apr 2.

25.

Direct hemoperfusion with a beta2-microglobulin-selective adsorbent column eliminates inflammatory cytokines and improves pulmonary oxygenation.

Kono K, Toda S, Hora K, Kiyosawa K.

Ther Apher Dial. 2009 Feb;13(1):27-33. doi: 10.1111/j.1744-9987.2009.00652.x.

PMID:
19379167
26.

Efficacy and safety of addition of minor bloodletting (petit phlebotomy) in hepatitis C virus-infected patients receiving regular glycyrrhizin injections.

Tanaka N, Horiuchi A, Yamaura T, Komatsu M, Yokoyama T, Okaniwa S, Nagaya T, Yoshizawa K, Kiyosawa K, Aoyama T, Tanaka E.

J Gastroenterol. 2009;44(6):577-82. doi: 10.1007/s00535-009-0034-x. Epub 2009 Apr 8.

PMID:
19352587
27.

Epidemiology of hepatocellular carcinoma in Japan.

Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K.

J Gastroenterol. 2009;44 Suppl 19:102-7. doi: 10.1007/s00535-008-2251-0. Epub 2009 Jan 16.

PMID:
19148802
28.

PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells.

Kono K, Kamijo Y, Hora K, Takahashi K, Higuchi M, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T.

Am J Physiol Renal Physiol. 2009 Feb;296(2):F328-36. doi: 10.1152/ajprenal.00484.2007. Epub 2008 Nov 26.

29.

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.

Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, Ichijo T, Yoshizawa K, Kiyosawa K, Tanaka E; Nagano Interferon Treatment Research Group.

Hepatology. 2008 Dec;48(6):1753-60. doi: 10.1002/hep.22543.

PMID:
18925643
30.

Development from simple steatosis to liver cirrhosis and hepatocellular carcinoma: a 27-year follow-up case.

Nagaya T, Tanaka N, Komatsu M, Ichijo T, Sano K, Horiuchi A, Joshita S, Umemura T, Matsumoto A, Yoshizawa K, Aoyama T, Kiyosawa K, Tanaka E.

Clin J Gastroenterol. 2008 Oct;1(3):116-121. doi: 10.1007/s12328-008-0017-0. Epub 2008 Jul 12.

PMID:
26193649
31.

Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan.

Umemura T, Tanaka E, Kiyosawa K, Kumada H; Japan de novo Hepatitis B Research Group.

Clin Infect Dis. 2008 Sep 1;47(5):e52-6. doi: 10.1086/590968.

PMID:
18643758
32.

Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease.

Komatsu M, Yazaki M, Tanaka N, Sano K, Hashimoto E, Takei Y, Song YZ, Tanaka E, Kiyosawa K, Saheki T, Aoyama T, Kobayashi K.

J Hepatol. 2008 Nov;49(5):810-20. doi: 10.1016/j.jhep.2008.05.016. Epub 2008 Jun 10.

PMID:
18620775
33.

Insulin resistance and hepatitis C virus: a case-control study of non-obese, non-alcoholic and non-steatotic hepatitis virus carriers with persistently normal serum aminotransferase.

Tanaka N, Nagaya T, Komatsu M, Horiuchi A, Tsuruta G, Shirakawa H, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, Kiyosawa K, Tanaka E.

Liver Int. 2008 Sep;28(8):1104-11. doi: 10.1111/j.1478-3231.2008.01737.x. Epub 2008 Apr 7.

PMID:
18397231
34.

Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with type 1 autoimmune hepatitis in Japanese.

Umemura T, Ota M, Yoshizawa K, Katsuyama Y, Ichijo T, Tanaka E, Kiyosawa K.

Hepatol Res. 2008 Jul;38(7):689-95. doi: 10.1111/j.1872-034X.2008.00337.x. Epub 2008 Mar 25.

PMID:
18371160
35.

Association of autoimmune pancreatitis with cytotoxic T-lymphocyte antigen 4 gene polymorphisms in Japanese patients.

Umemura T, Ota M, Hamano H, Katsuyama Y, Muraki T, Arakura N, Kawa S, Kiyosawa K.

Am J Gastroenterol. 2008 Mar;103(3):588-94. doi: 10.1111/j.1572-0241.2007.01750.x.

PMID:
18341485
36.

Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography.

Ozaki Y, Oguchi K, Hamano H, Arakura N, Muraki T, Kiyosawa K, Momose M, Kadoya M, Miyata K, Aizawa T, Kawa S.

J Gastroenterol. 2008;43(2):144-51. doi: 10.1007/s00535-007-2132-y. Epub 2008 Feb 29.

PMID:
18306988
37.

Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis.

Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T.

J Clin Gastroenterol. 2008 Apr;42(4):413-8. doi: 10.1097/MCG.0b013e31815591aa.

PMID:
18277895
38.

De novo autoimmune hepatitis following living-donor liver transplantation for primary biliary cirrhosis.

Yoshizawa K, Shirakawa H, Ichijo T, Umemura T, Tanaka E, Kiyosawa K, Imagawa E, Matsuda K, Hidaka E, Sano K, Nakazawa Y, Ikegami T, Hashikura Y, Miyagawa S, Ota M, Nakano M.

Clin Transplant. 2008 May-Jun;22(3):385-90. doi: 10.1111/j.1399-0012.2007.00787.x. Epub 2008 Jan 9.

PMID:
18190552
39.

PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice.

Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T.

J Clin Invest. 2008 Feb;118(2):683-94. doi: 10.1172/JCI33594.

40.

Pancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis.

Tanaka N, Horiuchi A, Yokoyama T, Kawa S, Kiyosawa K.

Am J Gastroenterol. 2008 Jan;103(1):245-6. doi: 10.1111/j.1572-0241.2007.01562_7.x. No abstract available.

PMID:
18184133
41.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
42.

PPARalpha protects proximal tubular cells from acute fatty acid toxicity.

Kamijo Y, Hora K, Kono K, Takahashi K, Higuchi M, Ehara T, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T.

J Am Soc Nephrol. 2007 Dec;18(12):3089-100. Epub 2007 Oct 31. No abstract available.

43.

Sclerosing cholangitis associated with autoimmune pancreatitis.

Kawa S, Hamano H, Umemura T, Kiyosawa K, Uehara T.

Hepatol Res. 2007 Oct;37 Suppl 3:S487-95.

PMID:
17931208
44.

Epidemiology of hepatocellular carcinoma in Japan.

Umemura T, Kiyosawa K.

Hepatol Res. 2007 Sep;37 Suppl 2:S95-S100.

PMID:
17877503
47.

Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis.

Umemura T, Zen Y, Hamano H, Kawa S, Nakanuma Y, Kiyosawa K.

Hepatology. 2007 Aug;46(2):463-71.

PMID:
17634963
48.

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

Ueno H, Kiyosawa K, Kaniwa N.

Br J Cancer. 2007 Jul 16;97(2):145-51. Epub 2007 Jun 26. Review.

49.

Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy.

Matsumoto A, Tanaka E, Minami M, Okanoue T, Yatsuhashi H, Nagaoka S, Suzuki F, Kobayashi M, Chayama K, Imamura M, Yotsuyanagi H, Nakaoka S, Maki N, Kawata S, Kumada H, Iino S, Kiyosawa K.

Hepatol Res. 2007 Aug;37(8):661-6.

PMID:
17584261
50.

IgG4 associated autoimmune hepatitis: a differential diagnosis for classical autoimmune hepatitis.

Umemura T, Zen Y, Hamano H, Ichijo T, Kawa S, Nakanuma Y, Kiyosawa K.

Gut. 2007 Oct;56(10):1471-2. Epub 2007 May 15. No abstract available.

Supplemental Content

Loading ...
Support Center